Value of Renal Vascular Doppler Sonography in Management of Decompensated Heart Failure

Study Overview
=================
Brief Summary
-----------------
Although the traditional determinant of renal dysfunction in heart failure was suggested as decreased cardiac output and renal hypo perfusion, recent studies have demonstrated the association of persistent systemic venous congestion and kidney dysfunction. Relief of the congestion has demonstrated to improve renal functions in decompensated heart failure. The current trial was set up to investigate the changes of renal venous impedance and renal arteriolar resistivity indices with diuretic therapy, in patients with congestive renal failure. The investigators asked whether measurement of renal venous impedance index or renal arteriolar resistivity index can guide the practice of diuretic therapy.

Official Title
-----------------
Value of Renal Vascular Doppler Sonography in Management of Decompensated Heart Failure

Conditions
-----------------
Cardiorenal Syndrome

Intervention / Treatment
-----------------
* Drug: intravenous furosemide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Decompensated heart failure Elevated serum creatinine levels on admission Exclusion Criteria: Atrial fibrillation Obstructive uropathy Patients with ascites Patients who exposed the potential nephrotoxic drugs in the previous week (metformin, antibiotics, chemotherapeutics, iodinated contrast agents and non-steroidal anti-inflammatory agents) Patients who needed positive inotropic agents

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group 1<br>Patients with type 1 cardiorenal syndrome who had improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment. | Drug: intravenous furosemide<br>* Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion<br>* Other names: Lasix;|
| Active Comparator: Group 2<br>Patients with type 1 cardiorenal syndrome who did not have improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment. | Drug: intravenous furosemide<br>* Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion<br>* Other names: Lasix;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Alterations in the renal arterial resistivity index | Participants will be followed for the duration of hospital stay, an expected average of 4 weeks. | during hospitalization, an expected average of 4 weeks. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Alterations in the renal venous impedance index | Participants will be followed for the duration of hospital stay, an expected average of 4 weeks. | during hospitalization, an expected average of 4 weeks. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiorenal syndrome, decompensated heart failure, renal resistivity index, venous impedance index, kidney failure